Please login to the form below

Not currently logged in
Email:
Password:

Cell Therapeutics

This page shows the latest Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Riva leaves Gilead to head Glenmark’s innovation spin-off

Riva leaves Gilead to head Glenmark’s innovation spin-off

by Antibodies based on the T cell receptor) platform. ... Attracting Riva to head up the new company is a coup for Glenmark, but a setback for Gilead, which only appointed him as head of its oncology and cell therapeutics in

Latest news

  • Roche buys gene therapy specialist Spark for $4.3bn Roche buys gene therapy specialist Spark for $4.3bn

    Can compete with rival Novartis in fast-developing area. Roche is set to transform its presence in advanced therapies with a $4.3bn deal to buy Spark Therapeutics, the first company ... The acquisition will inevitably increase expectation of more buyouts

  • AbbVie enters BCMA race with Teneobio deal AbbVie enters BCMA race with Teneobio deal

    Teneobio to co-develop and commercialise its B-cell maturation antigen (BCMA) targeting candidate. ... Teneobio says its “T-cell engaging cancer therapeutics are of the next wave or promising biologics, rivalling CAR-T cell therapy for efficacy, with

  • Novartis gets breakthrough tag from FDA for sickle cell drug Novartis gets breakthrough tag from FDA for sickle cell drug

    LentiGlobin is already under regulatory review in the EU for beta-thalassemia, another red blood cell disorder. ... Meanwhile, last week, the FDA also granted breakthrough status to a CRISPR-based gene-editing therapy for sickle cell in development at

  • MedCity sets up advanced therapy research network MedCity sets up advanced therapy research network

    UK companies operating int his area include university spinouts Orchard Therapeutics, Autolus, Cell Medica, GammaDelta and Quethera. ... Earlier this year, MedCity organised a showcase of cell and gene therapy expertise at eight National Institute for

  • FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

    enabling partners Vertex and CRISPR Therapeutics to begin the study by the end of 2018. ... The partners are developing it for both β-thalassemia and sickle cell disease (SCD).

More from news
Approximately 8 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... Acquisition. $2B. Tango Therapeutics/. Gilead Sciences. Pipeline of up to 5 targeted immuno‐oncology.

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign gynaecological disorders (marketed). ... Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies. ... acquisition - product. 190. Annapurna

  • Pharma deals in August 2015 Pharma deals in August 2015

    Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib. ... Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    Appoints Josh Hamermesh and Paul Nee. Cellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh. ... Alongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice

  • Rubius Therapeutics adds to its board of directors Rubius Therapeutics adds to its board of directors

    Francis Cuss and Catherine Sohn join the US biotech. US biotech Rubius Therapeutics has made two appointments to its board of directors with the addition of Francis Cuss and Catherine Sohn ... Alongside Cuss, Catherine Sohn, currently non-executive

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    Four new hires join the US-based company. Rubius Therapeutics, a company focused on creating Red-Cell Therapeutics, has bolstered its senior team with the addition of four new hires. ... Chris and the rest of the team will play a pivotal role in bringing

  • Bone Therapeutics strengthens clinical development team Bone Therapeutics strengthens clinical development team

    I look forward to working with the Bone Therapeutics team to realise the potential of its ground breaking products for the benefits of the patients.”. ... Thomas Lienard, chief executive officer at Bone Therapeutics, said: “His vast expertise in cell

  • David Epstein joins Flagship Pioneering as executive partner David Epstein joins Flagship Pioneering as executive partner

    In this newly-created position, Epstein will begin working with Rubius Therapeutics, a red blood cell-focused exploratory venture within the Flagship portfolio, as chairman of its board.

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... society. “We look at the manufacturing challenges we are facing for emerging healthcare products, such as

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics